ArticleNicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco2026
Oral Nicotine Pouches and Public Health: Evidence from an Updated Scoping Review.
Article in Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThe popularity of oral nicotine pouches (ONPs) is rising in the US and worldwide. This review provides an update on their potential public health impact.
methodsWe searched six electronic databases for ONP-related empirical studies through September 30, 2025, updating an earlier review. Outcomes included ONP product characteristics, use patterns, beliefs, perceptions, toxicity, sales, and marketing.
resultsWe identified 73 new studies published since our previous review (majority conducted in the US; 12 industry-funded). Data from heterogeneous national surveillance sources indicate a slow but steady increase in current ONP use prevalence among youth in 2024, with the National Youth Tobacco Survey (NYTS) reporting 1.8% prevalence among middle and high school students and the Monitoring the Future (MTF) study reporting 2.6% prevalence among 10th and 12th graders. Current use among adults was relatively low in 2022-2023 (0.4%-0.8%), with higher use among ages 18-44 and current tobacco users. US sales have more than tripled between 2021 and 2024. Marketing strategies increasingly emphasize potentially youth-appealing claims, with online and social media as key promotional channels. ONPs generally contain a higher proportion of freebase nicotine than other oral nicotine products and tobacco-containing pouches, with nicotine delivery increasing proportionally with nicotine strength. Nicotine uptake from higher strength ONPs (≥6mg) typically exceeds that from cigarettes in adult smokers, while ONPs consistently score lower in positive subjective ratings than cigarettes. Preliminary evidence from short-term, heterogeneous studies suggests that ONP use can reduce smoking in daily smokers, generally resulting in dual use rather than complete cigarette cessation. ONPs are considerably less toxic than cigarettes, but their long-term health impacts remain understudied.
conclusionsThe review underscores the need for further research on ONP health effects, their efficacy in long-term smoking cessation, and broader public health impact in tobacco-naïve populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.